On Thursday, the European Medicines Agency recommended approval for AstraZeneca’s COVID-19 prevention jab, which can be administered to individuals with issues with their immune system or severe reactions to regular vaccines.
The EMA human medicines committee stated that their recommendation “grants a marketing authorisation for Evusheld, developed by AstraZeneca for the prevention of COVID-19 in adults and adolescents from 12 years of age.”
Evusheld revealed that a test held on 5,000 people, who received two jabs, showed reduction of risk of COVID infection by 77 percent and protection for a period of six months.
The study was held before the emergence of the Omicron strain, with lab results showing that the “Omicron BA.1 variant may be less sensitive to tixagevimab and cilgavimab than the Omicron BA.2 variant.”
#MaltaDaily